Department of Medicine 5 – Haematology and Oncology

Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy (2022) Capellini A, Etra A, Alousi AM, Al Malki MM, Choe H, Defilipp Z, Hogan WJ, et al. Conference contribution Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection (2022) Buecklein VL, Perez-Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Conference contribution Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time (2022) Rejeski K, Perez AP, Iacoboni G, Buecklein VL, Blumenberg V, Völkl S, Penack O, et al. Conference contribution ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (2022) Ernst T, Schoenfeld L, Rinke J, Hinze A, Nagel SN, Schaefer V, Schenk T, et al. Conference contribution Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd (2022) Habenicht KM, Bootz A, Schäfer S, Vasova I, Fante M, Schneider A, Rehli M, et al. Conference contribution CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients (2022) Müller F, Völkl S, Mougiakakos D, Böltz S, Aigner M, Gary R, Kretschmann S, et al. Conference contribution Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1a-Mediated Apoptosis Following Unfolded Protein Response (2022) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Conference contribution Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity (2022) Pelzl R, Kübel S, Klein P, Gsottberger F, Wendland K, Petkovic S, Brueckl V, et al. Conference contribution Interprofessional Communication about Complementary and Integrative Health (CIH): Development and Implementation of a Training Program (2022) Behzad A, Stein B, Kaltenbach A, Lohmueller L, Kroeger B, Boltenhagen U, Joos S, et al. Conference contribution Expression of disialoganglioside GD2 in breast cancer subtypes (2022) Gaß P, Kailayangiri S, Hübner H, Rübner M, Hartmann A, Häberle L, Völkl S, et al. Conference contribution